2018
Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis
Perdigoto AL, Preston-Hurlburt P, Clark P, Long SA, Linsley PS, Harris KM, Gitelman SE, Greenbaum CJ, Gottlieb PA, Hagopian W, Woodwyk A, Dziura J, Herold KC. Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis. Diabetologia 2018, 62: 655-664. PMID: 30569273, PMCID: PMC6402971, DOI: 10.1007/s00125-018-4786-9.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntibodies, Monoclonal, HumanizedArea Under CurveAutoimmunityC-PeptideCD3 ComplexCD8-Positive T-LymphocytesChildCytokinesDiabetes Mellitus, Type 1FemaleFollow-Up StudiesHumansHypoglycemic AgentsInsulinIslets of LangerhansMaleRandomized Controlled Trials as TopicRemission InductionTreatment OutcomeYoung AdultConceptsC-peptide responseType 1 diabetesMixed meal tolerance testDetectable C-peptideC-peptideInsulin useTolerance testT cellsControl groupNew-onset type 1 diabetesPeripheral blood mononuclear cellsConclusions/interpretationThese findingsAnti-CD3 monoclonal antibodyDaily insulin useBlood mononuclear cellsDiagnosis of diabetesSuccessful immune therapiesOriginal control groupCell death proteinAnergic CD8ResultsFifty-sixImmune therapyInterpretationThese findingsMononuclear cellsCytokine release
2017
Microbiota control immune regulation in humanized mice
Gülden E, Vudattu NK, Deng S, Preston-Hurlburt P, Mamula M, Reed JC, Mohandas S, Herold BC, Torres R, Vieira SM, Lim B, Herazo-Maya JD, Kriegel M, Goodman AL, Cotsapas C, Herold KC. Microbiota control immune regulation in humanized mice. JCI Insight 2017, 2: e91709. PMID: 29093268, PMCID: PMC5752290, DOI: 10.1172/jci.insight.91709.Peer-Reviewed Original ResearchMeSH KeywordsAdaptive ImmunityAnimalsAntibodies, AntinuclearAntibodies, Monoclonal, HumanizedAutoimmune DiseasesB7-2 AntigenCD11b AntigenCD11c AntigenCD3 ComplexCD8-Positive T-LymphocytesCytokinesDisease Models, AnimalGastrointestinal MicrobiomeGastrointestinal TractGraft RejectionHumansImmunosuppressive AgentsImmunotherapyInterferon-gammaInterleukin-10Interleukin-27Leukocytes, MononuclearMiceMice, KnockoutMucous MembraneSkin TransplantationSTAT5 Transcription FactorT-LymphocytesTransplantation, HeterologousConceptsT cellsIL-10Humanized miceHuman peripheral blood mononuclear cellsPeripheral blood mononuclear cellsIL-27 expressionIL-10 levelsAnti-nuclear antibodiesEffector T cellsLevels of IFNCentral memory cellsLess IL-10Markers of efficacyBlood mononuclear cellsExpression of CD86Immune regulatory pathwaysIL-10 inductionHuman immune cellsHuman stool samplesImmunosuppressive medicationsIL-27Xenograft rejectionImmune therapyMononuclear cellsAntibiotic treatment
2014
Humanized Mice as a Model for Aberrant Responses in Human T Cell Immunotherapy
Vudattu NK, Waldron-Lynch F, Truman LA, Deng S, Preston-Hurlburt P, Torres R, Raycroft MT, Mamula MJ, Herold KC. Humanized Mice as a Model for Aberrant Responses in Human T Cell Immunotherapy. The Journal Of Immunology 2014, 193: 587-596. PMID: 24943216, PMCID: PMC4123131, DOI: 10.4049/jimmunol.1302455.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal GlandsAnimalsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAutoimmune DiseasesCytokinesDisease Models, AnimalFlow CytometryHumansInterleukin Receptor Common gamma SubunitIpilimumabLiverLymphocyte ActivationMacrophagesMiceMice, Inbred NODMice, KnockoutMice, SCIDPhosphorylationSTAT5 Transcription FactorStem Cell TransplantationSurvival AnalysisT-LymphocytesT-Lymphocytes, RegulatoryTransplantation, HeterologousWeight LossConceptsAnti-nuclear AbsAutoimmune diseasesRegulatory cellsHumanized miceT cellsImmune responseWeight lossMesenteric lymph nodesHuman autoimmune diseasesInduction of autoimmunityT-cell immunotherapyRelease of IFNHuman immune responseImmune-deficient miceIpilimumab treatmentInflammatory sequelaeLymph nodesCell immunotherapyIP-10Macrophage infiltrationCytokine productionSpleen cellsPathologic processesHepatitisMice
2012
Analysis of Human Biologics With a Mouse Skin Transplant Model in Humanized Mice
Waldron-Lynch F, Deng S, Preston-Hurlburt P, Henegariu O, Herold KC. Analysis of Human Biologics With a Mouse Skin Transplant Model in Humanized Mice. American Journal Of Transplantation 2012, 12: 2652-2662. PMID: 22900715, DOI: 10.1111/j.1600-6143.2012.04178.x.Peer-Reviewed Original ResearchConceptsSkin transplant modelGraft rejectionTransplant modelHumanized miceSkin graftsT cellsFunctional human immune responsesMouse skin transplant modelMurine skin transplant modelCentral memory T cellsNOD/SCID/Mouse skin graftsMemory T cellsMonoclonal antibody therapySkin graft rejectionDevelopment of effectorHuman immune responseMHC class IHuman T cellsIpilimumab treatmentAntibody therapySCID/Diffuse infiltrationMouse donorsSerum immunoglobulinsTeplizumab Induces Human Gut-Tropic Regulatory Cells in Humanized Mice and Patients
Waldron-Lynch F, Henegariu O, Deng S, Preston-Hurlburt P, Tooley J, Flavell R, Herold KC. Teplizumab Induces Human Gut-Tropic Regulatory Cells in Humanized Mice and Patients. Science Translational Medicine 2012, 4: 118ra12. PMID: 22277969, PMCID: PMC4131554, DOI: 10.1126/scitranslmed.3003401.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, Monoclonal, HumanizedCD3 ComplexCell MovementDiabetes Mellitus, Type 1Forkhead Transcription FactorsGastrointestinal TractHumansHypoglycemic AgentsInterleukin-10Intestine, SmallL-SelectinMiceMucous MembraneNatalizumabOligonucleotide Array Sequence AnalysisReceptors, CCR6T-Lymphocytes, RegulatoryConceptsHumanized micePeripheral circulationSmall intestineType 1 diabetes mellitusNovel immunologic mechanismIL-10 expressionTreatment of patientsType 1 diabetesSecondary lymph organsHuman immune cellsT cell migrationMechanism of actionGut-tropicImmunologic mechanismsRegulatory cellsDiabetes mellitusImmune therapyInterleukin-10Immune cellsRegulatory cytokinesClinical trialsPreclinical modelsClinical studiesT cellsHuman hematopoietic stem cells